Mar 2, 2010. SAGE Books The ultimate social sciences digital library. Thank you for visiting the Astellas Pharma Inc. Website. About Astellas Pharma Inc. Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The main produc ts include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others. Astellas publishes a statement for Modern Slavery Act 2015. (This link opens in a new window) Cancel Click here to leave this site. 3,4,5, “More than 24,000 people in Japan are diagnosed with urothelial cancer each year. 14. Latest materials on IR are available here. Number of Employees: 17, 454 Description: Manufacturer, distributor, importer/exporter of medical supplies Solution Challenge. Astellas Pharma Inc legal and financial information. Its focus areas include urology, immunology, cardiology, infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of … The submission is based on two global clinical trials with sites in Japan. The Focus Area, where we put our efforts, consists of combinations of three components: 1) biology, 2) modality/technology, 3) diseases. Astellas Pharma Inc. Investor Relations. (This link opens in a new window) Cancel Click here to leave this site. 1,2, Enfortumab vedotin met the primary endpoints of overall survival (EV-301) and confirmed objective response rate per blinded independent central review (EV-201). Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. History of the Former Yamanouchi Pharmaceutical Co., Ltd. 1923. However, there still remain barriers for many people who have difficulty accessing the healthcare they need due to the lack of available treatments, poverty, healthcare system challenges and insufficient healthcare information. Posted Financial Results for 3Q/FY2020. Jan 29, 2021. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. (RTTNews) - Astellas Pharma Inc. (ALPMY) and FibroGen, Inc. (FGEN) announced that Japan's Ministry of Health, Labour and Welfare approved … Provisionally the third fermentation building, the facility will be used to manufacture API of Astellas’ Prograf ® (tacrolimus hydrate), an anti-rejection medicine for liver, kidney and heart transplant patients. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. It shows a strong performance in its approach to compliance controls and health system strengthening, but has a small priority R&D pipeline and a few access plans. Updated “R&D Meeting” Section. Directors. GSK. Location: Tokyo, Japan Established: 1923 Capital: $1 B USD (approx.) SAGE Video Bringing teaching, learning and research to life. The Company mainly operates Pharmaceutical Products business segment. The Company mainly operates Pharmaceutical Products business segment. The Focus Area, where we put our efforts, consists of combinations of three components: 1) biology, 2) modality/technology, 3) diseases. SAGE Navigator The essential social sciences literature review tool. View 4503.JP financial statements in full. About Us Surims Ltd is a consultancy established in 2003 supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. TOKYO, March 11, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication. Review our consolidated business results, forecasts and financial data, etc. Astellas Pharma Inc., is a pharmaceutical company conducting business in more than 70 countries around the world. Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Oct 30, 2020. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others. Thank you for visiting the Astellas Pharma Inc. Website. Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the submission of a New Drug Application (NDA) to Japan… Thank you for visiting the Astellas Pharma Inc. Website. Astellas leverages our science-first mindset to turn medical advances into VALUE for patients. 2.33. Astellas participates in Access Accelerated. Contact for Potential Acquisition of Astellas’ R＆D programs. We are pursuing collaboration with the Best Science partners. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. The Phase 2 EV-201 trial evaluated enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor, including those who have also been treated with a platinum-containing chemotherapy (cohort 1) and those who have not received a platinum-containing chemotherapy and who are ineligible for cisplatin (cohort 2). Stock Quotes (TSE 1st:4503) View Stock Performance. Medical Care & Pharmaceutical Information, Rx+® - New Healthcare Solutions Beyond Medicine, Patient Outcome Maximization via Precise Surgery/Diagnosis, Communication with the World Anti-Doping Agency (WADA), Astellas Environment, Health & Safety Guidelines, Biodiversity and Astellas An Enlarged Version, The Biodiversity Burden Index and Revenue, Environmental Impact of Products and Countermeasures, Environment-related Investments and Expenses, Providing Opportunities for Employees to Succeed Globally, ISO certification status of Astellas plants, Basic policy for procurement activities involving suppliers, Research Activities on Tuberculosis and Malaria, Development of Pediatric Formulation for Schistosomiasis, Consolidated Financial Statements and Footnotes, Astellas Submits New Drug Application for Enfortumab Vedotin in Japan. GlaxoSmithKline, known globally as GSK, works in three main areas of … The Phase 3 EV-301 trial evaluated enfortumab vedotin versus chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor. Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Astellas Pharma is a leading pharmaceutical company in Japan with global business activities. Astellas Pharma Inc legal and financial information. (This link opens in a new window) Cancel Click here to leave this site. Rank. Astellas Pharma Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. President: Paul Relette. Astellas combats disease with the formidable combination of ground-breaking biology and modality/technology through our Focus Area approach. Biotech rejects unsolicited $3 billion bid from Japan's Astellas Pharma, says it would entertain a higher offer. Enfortumab vedotin to be reviewed by Ministry of Health, Labour and Welfare for patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication. Dec 10, 2020 . Get News Alerts by Email Year All Years 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 Category All Categories Corporate Corporate Awards Corporate Social Responsibility Our People Therapeutic Area News Uncategorized Keywords Go (This link opens in a new window) Cancel Click here to leave this site. Download this report card; x. Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha). Stories about how Astellas members work to create innovation, as well as achieve business and sustainability strategic goals. It has approximately 16,000 employees, and its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and . Performance. Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. TOKYO, March 11, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer … Astellas’ Efforts Against the Spread of COVID-19, Medical Care & Pharmaceutical Information, Rx+® - New Healthcare Solutions Beyond Medicine, Patient Outcome Maximization via Precise Surgery/Diagnosis, Research Activities on Tuberculosis and Malaria, Development of Pediatric Formulation for Schistosomiasis, Communication with the World Anti-Doping Agency (WADA), Five Fields of CSR-Based Management Diagram, Basic policy for procurement activities involving suppliers, Priority Areas of Astellas Domestic Social Contribution Activities, Astellas Environment, Health & Safety Guidelines, Biodiversity and Astellas An Enlarged Version, The Biodiversity Burden Index and Revenue, Environmental Impact of Products and Countermeasures, Environment-related Investments and Expenses, Providing Opportunities for Employees to Succeed Globally, Consolidated Financial Statements and Footnotes, Astellas Submits New Drug Application for Enfortumab Vedotin in Japan, Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Global Astellas Group Executives, Astellas Announces Positive Topline Results from Two Phase 3 Pivotal Global Trials of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Postmenopausal Women, Technology×Healthcare 2019 -The Challenge to Evolution: Connection between Healthcare and Technology-, Posted Presentation Slides for Conference Call, Astellas Launches its Corporate Website’s Stories Section. On February 5, 2020, the company announced management changes effective from April 1, 2020. You will enter external sites beyond here. IR News. SAGE Reference The complete guide for your research journey. The … The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China (as of January 2021). Thank you for visiting the Astellas Pharma Inc. Website. Thank you for visiting the Astellas Pharma Inc. Website. Case Study Cloud Security BR-CASE-013 In the past, the service and labor costs from providers were extremely high for activities such as monitoring website defacement. Astellas monitors Focus Areas from biology perspectives, modality/technology, and disease to identify promising areas for investment. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. SAGE Business Cases Real world cases at your fingertips. Astellas Pharma Inc. Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Sorry, you need to enable JavaScript to visit this website. Kenji Yamauchi founded Yamanouchi Yakuhin Shokai in Osaka. Astellas was established in 2005 through merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical CO., Ltd. and has a rich history spanning over 100 years. Don't Wait For Roche, Take The Money And Run. Astellas Pharma has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. Annual Report 2020 Integrated with the CSR report. Astellas Pharma Inc. Stock Exchange: Tokyo Stock Exchange Ticker: 4503 HQ: Tokyo, Japan Employees: 16,243. For those whose cancer progresses despite treatment with chemotherapy and immunotherapy, there is no standard treatment option currently,” said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head, Astellas. Sorry, you need to enable JavaScript to visit this website. Astellas Pharma Inc. is a Japan-based pharmaceutical company that operates its business in more than 70 countries around the world. Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. Astellas participates in Access Accelerated. CQ Press Your definitive resource for politics, policy and people. Prograf, an immunosuppressant for organ transplantation. Advances continue to be made in technology and medicine that address unmet medical needs. Stock analysis for Astellas Pharma Inc (4503:Tokyo) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Astellas has an average performance. Astellas Pharma unveiled its plans to construct an active pharmaceutical ingredient (API) manufacturing facility in Toyama, Japan, in January 2020. You will enter external sites beyond here. You will enter external sites beyond here. You will enter external sites beyond here. Yoshihiko … Their philosophy is “to contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products” and as an R&D type global pharmaceutical company, Astellas Pharma is actively developing businesses. (as of September 30, 2020) Number of shareholders: 94,344 Common stock Authorized: 9,000,000,000 Common stock Issued: 1,861,787,075 Breakdown of Shareholders by Type Top ten (10) principal shareholders in the register … Astellas monitors Focus Areas from biology perspectives, modality/technology, and disease to identify promising areas for investment. Thank you for visiting the Astellas Pharma Inc. Website. Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan. About Us Surims Ltd is a consultancy established in 2003 supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations. 14th place. ASTELLAS PHARMA INC, Address: 2-5-1 Nihonbashi-Honcho Chuo-ku,Tokyo 103-8411 Phone : +81-3-3244-3000Homepage: https://www.astellas.com/: https://www.astellas.com/ Astellas Pharma Inc. is a pharmaceutical company focused on the development of innovative drugs and medical solutions. If approved, enfortumab vedotin would be the first antibody-drug conjugate (ADC) available in Japan for people living with this form of urothelial cancer. Astellas Pharma Hong Kong Co., Ltd. (Hong Kong) Astellas Pharma Taiwan, Inc. (Taiwan) Astellas Pharma Korea, Inc. (Korea) Astellas Pharma Philippines, Inc. (Philippines) Astellas Pharma (Thailand) Co., Ltd. (Thailand) P.T. Score. Stories about how Astellas members work to create innovation, as well as achieve business and sustainability strategic goals. “Based on data from two global clinical trials, and following the Ministry of Health, Labour and Welfare’s review, enfortumab vedotin may offer a new option for these patients.”, Click below for a copy of the full press release.